The Global Xerostomia Therapeutics Market Size was estimated at USD 610.65 million in 2017 and is anticipated to gain significant traction over coming years.
Xerostomia, also known as dry mouth, is a clinical condition occurred due to the absence or reduced production of saliva. Xerostomia may also arise owing to alteration in the saliva quality to hold the mouth wet. Generally, xerostomia is initiated due to a number of factors such as, a side effect of a radiation to the head and neck, dehydration, side-effects from medication, mouth bleeding, smoking, or surgery accomplished with the usage of radiation therapies. In addition, the most common factor causing xerostomia is Sjogren's syndrome, HIV and cancer treatments. Usually, the xerostomia is not considered or categorized as a disease however, the xerostomia shows the indications of several disorders. This condition is highly observed in geriatric populations. According to the oral cancer foundation reports, Xerostomia is common in elderly population affecting approximately 20% of the geriatric people, and are often associated with the functions of salivary glands. This ailment is primarily coupled with the other disorders including sore throat, verbal difficulties, hoarseness, burning sensation, and gulping. If this condition stays untreated, then it may outcome in decrease in oral pH and increase in the chances to develop dental caries or plaque. The xerostomia can be treated through self-care or intake of synthetic saliva or saliva alternatives such as mucopolysaccharides solutions or carboxymethyl. Moreover, the drugs to treat xerostomia includes saliva stimulants such as cevimeline or pilocarpine, and many others.
The global market growth for xerostomia therapeutics is majorly driven by the growing occurrence of the associated diseases. The most common diseases causing xerostomia includes HIV and Sjogren’s syndrome. According to the American College of Rheumatology, around 3.1 million individuals are suffering from Sjogren's syndrome in the U.S. Moreover, growing implementation of radiotherapy and chemotherapy in cancer treatment associated with rising in the use of prescribed medicines demanding appropriate care is anticipated to significantly enhance the market growth.
However, lack of awareness regarding the treatment in lower in middle-income region and non-availability of effective treatment is anticipated to hinder the market growth.
The global Xerostomia Therapeutics Market is segmented on the basis of product, distribution channel, and geography.
On the basis of product, the global xerostomia therapeutics market is segmented into Artificial Saliva, Dentifrices, Salivary Stimulants, Saliva Substitutes, Drugs, and Salivary Pen. On the basis of products, dentifrices segment is estimated to dominate the market. The dominance is primarily due to affordability, availability, effectiveness, higher adoption amongst the users. On the basis of the distribution channel, the global xerostomia therapeutics market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. In 2017, the hospital pharmacy is anticipated to dominate the market. The dominance of hospital pharmacy is majorly due to the availability of limited branded drugs, safety & efficacy, safety, and low pricing of products.
In terms of geography, North America is estimated to dominated the Xerostomia Therapeutics Market with the largest share in 2017 followed by Europe. The major factors subsidizing toward dominance are growing occurrence of xerostomia cases and other diseases related to dry mouths such as rheumatoid arthritis, HIV, and Sjogren’s syndrome. For instance, Sjogren Syndrome Foundation of the U.S. is responsible for conducting awareness regarding the treatments and cure for the patients with xerostomia in the U.S. and Canada. In addition, growing healthcare substructure and amenities, easy obtainability of proper treatment options, and favorable reimbursement scenario is the factors enhancing the market growth in North America.
However, Asia Pacific is anticipated to make a dominating growth for Xerostomia Therapeutics Market during the forecast period. growing healthcare spending, the rise in inventiveness for growing awareness, and increasing occurrence of ailments such as Parkinson’s disease, diabetes, cancer, and HIV causing dry mouth conditions and factors estimated to bolster the xerostomia therapeutics market in the Asia Pacific.
Major firms are focusing on small firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global Xerostomia Therapeutics Market includes Eisai Inc., Colgate-Palmolive Company, Dentaid, EUSA Pharma, Forward Science, GlaxoSmithKline plc, Mission Pharmacal Company, OraHealth Inc., OraPharma, Inc., Parnell Pharmaceuticals, Inc., Saliwell Ltd., and Sun Pharmaceutical Industries Limited among others.